Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nabil Amirouchene-Angelozzi

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Cancer Discovery|July 22, 2017
Tumor Evolution as a Therapeutic TargetNabil Amirouchene-Angelozzi, Charles Swanton, Alberto Bardelli
Cancer Discovery|November 17, 2018
The Clinical Impact of the Genomic Landscape of Mismatch Repair-Deficient CancersGiovanni Germano, Nabil Amirouchene-Angelozzi, Giuseppe Rospo, et al.
British Journal of Cancer|December 24, 2015
Upcoming translational challenges for uveal melanomaNabil Amirouchene-Angelozzi, Marie Schoumacher, Marc-Henri Stern, et al.
British Journal of Cancer|October 28, 2015
Upcoming translational challenges for uveal melanomaNabil Amirouchene-Angelozzi, Marie Schoumacher, Marc-Henri Stern, et al.
Oncotarget|March 19, 2016
The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanomaNabil Amirouchene-Angelozzi, Estelle Frisch-Dit-Leitz, Guillaume Carita, et al.
Molecular Oncology|July 5, 2014
Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic targetNabil Amirouchene-Angelozzi, Fariba Nemati, David Gentien, et al.
Genome Medicine|June 30, 2019
Evolving neoantigen profiles in colorectal cancers with DNA repair defectsGiuseppe Rospo, Annalisa Lorenzato, Nabil Amirouchene-Angelozzi, et al.
Nature|November 30, 2017
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growthGiovanni Germano, Simona Lamba, Giuseppe Rospo, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Cancer Discovery|July 22, 2017
Tumor Evolution as a Therapeutic TargetNabil Amirouchene-Angelozzi, Charles Swanton, Alberto Bardelli
Cancer Discovery|November 17, 2018
The Clinical Impact of the Genomic Landscape of Mismatch Repair-Deficient CancersGiovanni Germano, Nabil Amirouchene-Angelozzi, Giuseppe Rospo, et al.
British Journal of Cancer|December 24, 2015
Upcoming translational challenges for uveal melanomaNabil Amirouchene-Angelozzi, Marie Schoumacher, Marc-Henri Stern, et al.
British Journal of Cancer|October 28, 2015
Upcoming translational challenges for uveal melanomaNabil Amirouchene-Angelozzi, Marie Schoumacher, Marc-Henri Stern, et al.
Oncotarget|March 19, 2016
The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanomaNabil Amirouchene-Angelozzi, Estelle Frisch-Dit-Leitz, Guillaume Carita, et al.
Molecular Oncology|July 5, 2014
Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic targetNabil Amirouchene-Angelozzi, Fariba Nemati, David Gentien, et al.
Genome Medicine|June 30, 2019
Evolving neoantigen profiles in colorectal cancers with DNA repair defectsGiuseppe Rospo, Annalisa Lorenzato, Nabil Amirouchene-Angelozzi, et al.
Nature|November 30, 2017
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growthGiovanni Germano, Simona Lamba, Giuseppe Rospo, et al.
Pageof 1